The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
ORGANIZATION
4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
The Japanese government’s decision late last year on the FY2025 drug price revision marks a de facto repeal of the so-called “four ministers’ agreement” of 2016, with fresh discussions now warranted on the future of the off-year scheme, says Yasushi…
To read the full story
ORGANIZATION
- Payer Kyokai Kenpo Ups Target for Biosimilar Use
March 25, 2025
- FPMAJ Maps Out Planned Activities for FY2025
March 24, 2025
- JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
March 10, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…